Simple Risk Score Predicts Severe Cisplatin-Linked Acute Kidney Injury
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 27, 2024 -- A simple risk score consisting of nine covariates predicts the risk for severe cisplatin-associated acute kidney injury (CP-AKI), according to a study published online March 27 in The BMJ.
Shruti Gupta, M.D., from Brigham and Women's Hospital in Boston, and colleagues developed and externally validated a prediction model for severe CP-AKI in a multicenter cohort study involving adults receiving their first dose of intravenous cisplatin in 2006 to 2022. Independent predictors of CP-AKI were identified using a multivariable logistic regression model, which was developed and tested in a derivation cohort (11,766 adults) and an external validation cohort (12,951 adults).
The researchers found that the incidence of CP-AKI was 5.2 and 3.3 percent in the derivation and validation cohorts, respectively. Age, hypertension, diabetes mellitus, serum creatinine level, hemoglobin level, white blood cell count, platelet count, serum albumin level, serum magnesium level, and cisplatin dose were independently associated with CP-AKI. A simple risk score composed of nine covariates predicted a higher risk for CP-AKI in a monotonic manner in the derivation and validation cohorts. Patients in the highest- versus the lowest-risk category had 24.00- and 17.87-fold increased odds in the derivation and validation cohorts, respectively. The C-statistic for the primary model was 0.75, and it showed better discrimination than previously published models (range, 0.60 to 0.68). A monotonic association was seen for greater severity of CP-AKI with shorter 90-day survival (adjusted hazard ratio, 4.63 for stage 3 versus no CP-AKI).
"This model should help providers weigh the risks and benefits of cisplatin and will allow for enrichment of prospective studies designed to prevent CP-AKI," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Women Face Worse Chronic Kidney Disease Management in Primary Care
MONDAY, May 20, 2024 -- Women receive worse primary care-based chronic kidney disease (CKD) management than men, according to a research letter published online May 16 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.